Siedlerstraße 7 | 68623 Lampertheim, Germany

info@zamann-pharma.com

Innovations and highlights in the Pharma industry 

Dive deep into the world of Pharma with Zamann’s Expert Blog. Our industry-leading professionals share insights on global project management, quality consultancy, digitalization, and more. Stay updated with trends and innovations transforming the Pharma industry. 

IQ, OQ, PQ: Essential Steps for Equipment Qualification

Equipment quality in pharmaceutical manufacturing is ensured through IQ, OQ, and PQ phases, validating installation, performance, and user needs. Regulatory mandates prevent hazards, like mislabeling, with ongoing compliance via requalification. Expert guidance streamlines validation efforts for robust, compliant systems.

What is GAMP 5 Guideline? Checklist for GAMP 5 compliance

GAMP is the acronym used to summarize the term “Good Automated Manufacturing Practices“. These are a compilation of recommendations published by the International Society for Pharmaceutical Engineering (ISPE) in the form of a book to provide guidance on the compliance of computerized systems in regulated industries.

Unveiling GMP Inspections: Key Deficiencies and Guidelines

In the pharmaceutical industry, GMP inspections ensure quality and compliance, demonstrating commitment to safety and building trust with healthcare professionals and patients. Understanding the inspection process, guidelines, and common deficiencies is crucial for upholding industry standards and ensuring patient safety.

News and more

This article explains why ISO-certified pharmaceutical organizations still face GMP inspection findings, how regulators interpret GMP versus ISO in practice, and what inspection-driven quality oversight requires beyond certification to achieve true regulatory inspection readiness.
Inspection-driven analysis of CSV vs Annex 11 highlighting why validated computerized systems still trigger findings. This article explains regulatory expectations, common inspection gaps, and how governance, data integrity, and lifecycle control shape inspection outcomes in GMP environments
GMP inspections increasingly show that weaknesses in terminal sterilization signal broader sterility assurance governance gaps. This article explains how inspectors assess control systems, why validated cycles still fail scrutiny, and what manufacturers must demonstrate to reduce critical findings.
Inspection-focused analysis of cross contamination in pharmaceutical manufacturing, explaining why regulators classify control failures as critical GMP findings and how weaknesses in segregation, cleaning validation, and flow design drive inspection outcomes.
This article explains how regulators distinguish between GMP and cGMP during inspections, why “current” compliance matters, and how governance gaps lead to inspection findings. It provides practical insight for quality, manufacturing, and compliance leaders preparing for regulatory revie
This article explores how regulators assess manufacturing quality systems during inspections, why governance failures drive critical observations, and how structured oversight improves inspection readiness, reduces compliance risk, and supports consistent decision-making across pharmaceutical operations.
This article explains how regulators assess the Pharmacovigilance System Master File during inspections, where governance gaps create audit findings, and why clear accountability, traceability, and inspection readiness determine long-term regulatory confidence.
An inspection-driven overview explaining how regulators assess benefit–risk narratives in PBRERs, where governance gaps trigger repeat findings, and how structured oversight across reporting cycles strengthens compliance and regulatory confidence in pharmacovigilance systems.